Geographically, this report split global into several key Regions, with sales (K Units), revenue (M USD), market share and growth rate of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs for these regions, from 2014 to 2026 (forecast), covering
China
USA
Europe
Japan
Korea
India
Southeast Asia
South America
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market competition by top manufacturers/players, with Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales volume, Price (USD/Unit), revenue (M USD) and market share for each manufacturer/player; the top players including
AstraZenenca
Astellas Pharmaceuticals
Salix Pharmaceuticals Ltd
GlaxoSmithKline
Actavis
Pfizer
...
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Preface
Eluxadoline
Alosetron
Rifaximin
Loperamide
Diphenoxylate + Atropine
Dicyclomine and Hyoscyamine
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs for each application, including
Hospitals
Clinics
Others
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
1 Executive Summary
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Analysis by Types
2.1 Overall Market Performance(Volume)
2.1.1 Preface
2.1.2 Eluxadoline
2.1.3 Alosetron
2.1.4 Rifaximin
2.1.5 Loperamide
2.1.6 Diphenoxylate + Atropine
2.1.7 Dicyclomine and Hyoscyamine
2.2 Overall Market Performance(Value)
2.2.1 Preface
2.2.2 Eluxadoline
2.2.3 Alosetron
2.2.4 Rifaximin
2.2.5 Loperamide
2.2.6 Diphenoxylate + Atropine
2.2.7 Dicyclomine and Hyoscyamine
3 Product Application Market
3.1 Overall Market Performance (Volume)
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
4 Manufacturers Profiles/Analysis
4.1 AstraZenenca
4.1.1 AstraZenenca Profiles
4.1.2 AstraZenenca Product Information
4.1.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Sales Value(Million USD), Price and Gross Profit
4.1.4 AstraZenenca SWOT Analysis
4.2 Astellas Pharmaceuticals
4.2.1 Astellas Pharmaceuticals Profiles
4.2.2 Astellas Pharmaceuticals Product Information
4.2.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) DrugsSales, Sales Value (Million USD), Price and Gross Profit
4.2.4 Astellas Pharmaceuticals SWOT Analysis
4.3 Salix Pharmaceuticals Ltd
4.3.1 Salix Pharmaceuticals Ltd Profiles
4.3.2 Salix Pharmaceuticals Ltd Product Information
4.3.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) DrugsSales, Sales Value (Million USD), Price and Gross Profit
4.3.4 Salix Pharmaceuticals Ltd SWOT Analysis
4.4 GlaxoSmithKline
4.4.1 GlaxoSmithKline Profiles
4.4.2 GlaxoSmithKline Product Information
4.4.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) DrugsSales, Sales Value (Million USD), Price and Gross Profit
4.4.4 GlaxoSmithKline SWOT Analysis
4.5 Actavis
4.5.1 Actavis Profiles
4.5.2 Actavis Product Information
4.5.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) DrugsSales, Sales Value (Million USD), Price and Gross Profit
4.5.4 Actavis SWOT Analysis
4.6 Pfizer
4.6.1 Pfizer Profiles
4.6.2 Pfizer Product Information
4.6.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) DrugsSales, Sales Value (Million USD), Price and Gross Profit
4.6.4 Pfizer SWOT Analysis
5 Market Performance for Manufacturers
5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Market Share by Manufacturers 2014-2020
5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Market Share by Manufacturers 2014-2020
5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2014-2020
5.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2014-2020
5.5 Market Concentration
6 Regions Market Performance for Manufacturers
6.1 China Market Performance for Manufacturers
6.1.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.1.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.1.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.1.4 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2014-2020
6.1.5 Market Concentration
6.2 USA Market Performance for Manufacturers
6.2.1 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.2.2 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.2.3 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.2.4 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2014-2020
6.2.5 Market Concentration
6.3 Europe Market Performance for Manufacturers
6.3.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.3.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.3.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.3.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2014-2020
6.3.5 Market Concentration
6.4 Japan Market Performance for Manufacturers
6.4.1 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.4.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.4.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.4.4 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2014-2020
6.4.5 Market Concentration
6.5 Korea Market Performance for Manufacturers
6.5.1 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.5.2 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.5.3 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.5.4 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2014-2020
6.5.5 Market Concentration
6.6 India Market Performance for Manufacturers
6.6.1 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.6.2 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.6.3 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.6.4 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2014-2020
6.6.5 Market Concentration
6.7 Southeast Asia Market Performance for Manufacturers
6.7.1 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.7.2 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.7.3 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.7.4 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2014-2020
6.7.5 Market Concentration
6.8 South America Market Performance for Manufacturers
6.8.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2014-2020
6.8.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
6.8.3 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2014-2020
6.8.4 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2014-2020
6.8.5 Market Concentration
7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Assessment by Regions (2014-2020)
7.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Market Share by Regions 2014-2020
7.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Market Share by Regions 2014-2020
7.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Regions 2014-2020
7.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin by Regions 2014-2020
8 Development Trend for Regions
8.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
8.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
8.3 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
8.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
8.5 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
8.6 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
8.7 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
8.8 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
8.8 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate 2014-2020
9 Upstream Source, Technology and Cost
9.1 Upstream Source
9.2 Technology
9.3 Cost
10 Channel Analysis
10.1 Market Channel
10.2 Manufacturing Plants Distribution
11 Consumer Analysis
11.1 Hospitals Industry
11.2 Clinics Industry
11.3 Others Industry
12 Market Forecast 2021-2026
12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
12.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
12.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Growth Rate 2021-2026
12.1.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.4 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.6 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.7 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.8 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.9 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.10 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.2 Sales (K Units), Revenue (M USD) Forecast by Types 2021-2026
12.2.1 Overall Market Performance
12.2.2 Preface
12.2.3 Eluxadoline
12.2.4 Alosetron
12.2.5 Rifaximin
12.2.6 Loperamide
12.2.7 Diphenoxylate + Atropine
12.2.8 Dicyclomine and Hyoscyamine
12.3 Sales (K Units) Forecast by Application 2021-2026
12.3.1 Overall Market Performance
12.3.2 Hospitals
12.3.3 Clinics
12.3.4 Others
12.4 Price (USD/Unit) and Gross Profit
12.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) Trend 2021-2026
12.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Profit Trend 2021-2026
13 Conclusion